Abstract
This paper presents the most important cycles related to the pharmaceutical sector’s emergence, pointing out the main intra-industry links that, by letting firms benefit from the expansion opportunities, contributed to the consolidation of the sector in national, regional, and global terms. The main pharmaceutical industry’s evolutionary cycles are discussed. For each one, economic factors exogenous to the industry are presented. Those factors, combined with the biggest firms’ goals, led to scientific advances. Such advances, along with commercial and financial revenues and asset establishment, were concentrated in the big companies, granting them competitive advantages and innovative leadership in the sector. At the end are presented consequences for the value chain of the last evolutive cycle of pharmaceutical industry. New institutions and new forms of research had increased its importance to allow the entry of actors in the sectoral system, an unthinkable fact in previous cycles.References
Achilladelis, B.; Antonakis, N. “The dynamics of technological innovation: the case of the pharmaceutical industry”, Research Policy, v.30, p.535-588, 2001.
Casper, S.; Matraves, C. “Institutional frameworks and innovation in the German and UK pharmaceutical industry”, Research Policy, v.32, n.10, p.1.865-1.879, 2003.
Christensen, C.M. The innovators dilemma: when new technologies cause great firms to fail, Harvard Business School Press, 1997.
Cockburn, I.; Henderson, R. “Scale, scope, and spillovers: the determinants of research productivity in drug discovery”, RAND Journal of Economics, v.27, n.1, p.32-59, 1996.
Cockburn, I.; Henderson, R.; Scott, S. “The diffusion of science-driven drug discovery: organizational change in pharmaceutical research”, NBER Working Papers, n.7.359, National Bureau of Economic Research, Inc., 1999.
Cockburn, I. “Balancing incentives: the tension between basic and applied research”, NBER Working Papers, n.6.882, 1999.
Dosi, G. Technical change and industrial transformation: the theory and an application to the semiconductor industry, Londres: Macmillan, 1984.
Dosi, G.; Teece, D.; Winter, S. “Toward a theory of corporate coherence: preliminary remarks”, in Dosi, G.; Giannetti, R.; Toninelli, P.A., Technology and enterprise in a historical perspective, Nova York: Oxford University Press, 1992.
Gambardella, A.; Orsenigo, L.; Pammolli, F. “Global competitiveness in pharmaceuticals. A European perspective”, Report prepared for the Directorate General Enterprise of the European Commission, 2000.
Gilsing, V.; Nooteboom, B. “Co-evolution in innovation systems: the case of pharmaceutical biotechnology”, Eindhoven Centre for Innovation Studies, v.4, n.9, maio, 2004.
Hopkins, M.M. “An examination of technology strategies for the integration of bioinformatics in pharmaceutical R&D processes”, SPRU Electronic Working Papers Series, n.32, p.1-75, Brighton: SPRU, 1998.
Hulse, J.H. “Biotechnologies: past history, present state and future prospects”, Food Science Technology, v.15, p.3-18, 2004.
Lacasa, I. “Understanding technology adoption in the German pharmaceutical industry”, DRUID Academy Winter, 2003.
Lacetera, N. “Corporate governance and innovation in the pharmaceutical industry: some further evidence”, Working Paper Essy, p.1-28, 2000.
Malerba, F.; Orsenigo, L. “Innovation and market structure in dynamics of the pharmaceutical industry and biotechnology: towards a history friendly model”, Industrial Corporate Change, v.11, n.4, p.667-703, 2001.
Malerba, F. “Sectoral systems of innovation and production”, Research Policy, v.31, p.247-264, 2002.
Matraves, C. “Market structure, R&D and advertising in the pharmaceutical industry”, Journal of Industrial Economics, v.47, n.2, p.169-194, 1999.
McKelvey, M.; Orsenigo, L. “Pharmaceuticals as a sectoral innovation system”, Paper prepared for the ESSY Project (European Sectoral Systems of Innovation) and within the Epris Project, 2001.
Mirowski, P.; Van Horn, R. “The contract research organization and the commercialization of scientific research”, Social Studies of Science, v.35, n.4, p.503-548, 2005.
Mowery, D.C.; Rosenberg, N. Paths of innovation: technological change in 20th century america, Cambridge, UK: Cambridge University Press, 1998.
Nightingale, P. “Economies of scale in experimentation: knowledge and technology in pharmaceutical R&D”, Industrial and Corporate Change, v.9, n.2, 2000.
Orsenigo, L.F.; Pammolli, F.; Riccaboni, M. “The dynamics of knowledge and the evolution of an industry network. Lessons from pharmaceuticals”, Journal of Management and Governance, v.1, n.2, 1999.
Orsenigo, L.F. “Technological change and network dynamics: lessons from the pharmaceutical industry”, Research Policy, v.30, p.485-508, 2001.
Pisano, G.P. “The governance of innovation: vertical integration and collaborative arrangements in the biotechnology industry”, Research Policy, v.20, p.237-249, 1991.
Radaelli, V. “A inovação na indústria farmacêutica: forças centrípetas e forças centrífugas no processo de internacionalização”, Dissertação de Mestrado em Política Científica e Tecnológica, Instituto de Geociências, Universidade Estadual de Campinas, Campinas, 2006.
Silveira, J.M.F.J.; Futino, A.M.; Olalde, A.R., “O desenvolvimento recente da biotecnologia e a emergência de novos arranjos tecnológicos e financeiros”, Economia e Sociedade, v.11, n.1, p.129-165, Campinas, 2002.
Tushman, M.L.; Anderson, P. “Technological discontinuities and organizational environments”, Administrative Science Quarterly, 31, p.439-465, 1986.
Zucker, L.G.; Darby, M.R. “Present at the revolution: transformation of technical identity for a large incumbent pharmaceutical firm after the biotechnological breakthrough”, Research Policy, v.26, p.429-447, 1997.
The content of the articles and reviews published in RBI are of absolute and exclusive responsibility of their authors.
Downloads
